CADTH reimbursement recommendation: Luspatercept (Reblozyl)
Approximately 4 people per 100,000 persons in Canada are diagnosed with a myelodysplastic syndrome each year. UNMET NEEDS IN MYELODYSPLASTIC SYNDROMES: There is a need for a treatment that reduces the frequency of blood transfusions in patients who fail erythropoietin-based therapy and improves pati...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2021, 2021
|
| Series: | CADTH reimbursement review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Approximately 4 people per 100,000 persons in Canada are diagnosed with a myelodysplastic syndrome each year. UNMET NEEDS IN MYELODYSPLASTIC SYNDROMES: There is a need for a treatment that reduces the frequency of blood transfusions in patients who fail erythropoietin-based therapy and improves patients' quality of life. HOW MUCH DOES REBLOZYL COST? Treatment with Reblozyl is expected to cost between $152,188 to $228,281 per patient annually Evidence from 1 study showed that more patients who received Reblozyl did not need a blood transfusion than patients who received placebo.2. Patients expressed the need to reduce blood transfusions, and evidence from the reviewed study suggests that Reblozyl may meet some of the needs expressed by patients.3. Based on public list prices, Reblozyl is not cost-effective compared with best supportive care (RBC transfusions and iron chelators).4. The cost of Reblozyl needs to be reduced by 85% for it to be considered cost-effective at a $50,000 per quality-adjusted life-year threshold.5. Based on public list prices, Reblozyl will cost the public drug plans $101,479,111 in the first 3 years. ADDITIONAL INFORMATION: WHAT ARE MYELODYSPLASTIC SYNDROMES? Myelodysplastic syndromes are a group of diseases that prevent the body from making healthy blood cells. Patients may need frequent blood transfusions and may develop blood cancer. WHAT IS THE CADTH REIMBURSEMENT RECOMMENDATION FOR REBLOZYL? CADTH recommends that Reblozyl should be reimbursed by public drug plans for the treatment of adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS)-associated anemia who have ring sideroblasts and require red blood cell (RBC) transfusions, if certain conditions are met.WHICH PATIENTS ARE ELIGIBLE FOR COVERAGE? Reblozyl should only be covered to treat patients who have failed or are not suitable for erythropoietin-based therapy. WHAT ARE THE CONDITIONS FOR REIMBURSEMENT? Reblozyl should only be reimbursed if prescribed by a specialist in MDS and if the cost of Reblozyl is reduced. Reimbursement should only be renewed if Reblozyl shows benefit to the patient such that the patient no longer requires RBC transfusions. WHY DID CADTH MAKE THIS RECOMMENDATION? 1. |
|---|---|
| Physical Description: | 1 PDF file (16 pages) |